Neuronetics发布的真实数据显示NeuStar TMS对青少年和年轻人的抗抑郁作用

Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the publication of significant real-world findings in the Journal of the American Academy of Child & Adolescent Psychiatry Open (JAACAP Open), a leading peer-reviewed medical journal covering pediatric psychiatry. The study found strong antidepressant treatment effects in adolescent and young adult patients treated with NeuroStar TMS (transcranial magnetic stimulation). The results in these adolescent and young adult patients were consistent with those previously reported in adults.1